2024
Updated Comparative Efficacy of Ciltacabtagene Autoleucel Versus Idecabtagene Vicleucel in Patients with Relapsed or Refractory Multiple Myeloma Previously Treated with 2-4 Prior Lines of Therapy Using a Matching-Adjusted Indirect Comparison
Lopez-Muñoz N, Bar N, Diels J, van Sanden S, Mendes J, Lee S, Hernando T, Lendvai N, Patel N, Ishida T, Er J, Harrison S, Shah U. Updated Comparative Efficacy of Ciltacabtagene Autoleucel Versus Idecabtagene Vicleucel in Patients with Relapsed or Refractory Multiple Myeloma Previously Treated with 2-4 Prior Lines of Therapy Using a Matching-Adjusted Indirect Comparison. Blood 2024, 144: 3390. DOI: 10.1182/blood-2024-201568.Peer-Reviewed Original ResearchProgression-free survivalRelapsed/refractory multiple myelomaUnanchored matching-adjusted indirect comparisonMatching-adjusted indirect comparisonCilta-celIde-celCARTITUDE-1Overall survivalMultiple myelomaCAR-TIdecabtagene vicleucelIndirect comparisonsProteasome inhibitorsKaplan-MeierChimeric antigen receptor T cellsHazard ratioPresence of extramedullary diseaseAnti-CD38 monoclonal antibodyTreatment of adult patientsB-cell maturation antigenRisk of disease progressionConfidence intervalsTreatment of multiple myelomaRefractory to lenalidomideCAR-T treatmentLong-Term Benefits in Patient-Reported Outcomes and Time to Next Anti-Myeloma Therapy of Ciltacabtagene Autoleucel (Cilta-cel) Versus Standard of Care for Patients with Lenalidomide-Refractory Multiple Myeloma: Results from the Phase 3 Cartitude-4 Clinical Trial
Bar N, Mina R, Mylin A, Yokoyama H, Magen H, Alsdorf W, Minnema M, Shune L, Isufi I, Harrison S, Shah U, De Champlain A, Gries K, Chen D, Li Q, Yeh T, Slaughter A, Lonardi C, Benachour N, Ghosh A, Deraedt W, Vogel M, Lendvai N, Patel N, Costa Filho O, Florendo E, Karlin L, Weisel K. Long-Term Benefits in Patient-Reported Outcomes and Time to Next Anti-Myeloma Therapy of Ciltacabtagene Autoleucel (Cilta-cel) Versus Standard of Care for Patients with Lenalidomide-Refractory Multiple Myeloma: Results from the Phase 3 Cartitude-4 Clinical Trial. Blood 2024, 144: 2002-2002. DOI: 10.1182/blood-2024-209232.Peer-Reviewed Original ResearchProgression-free survivalAnti-myeloma therapyLenalidomide-refractory multiple myelomaCilta-celMedian follow-upFollow-upMultiple myelomaStandard of careCiltacabtagene autoleucelProgressive diseaseMedian timeSOC armRefractory to lenalidomideYears of follow-upAnti-myeloma treatmentKaplan-Meier methodData cut-offCox proportional hazards modelsConfidence intervalsWorsening of symptomsRisk of deathProportional hazards modelFunctional impactEuropean Organization for ResearchMM patients
2023
Comparative Efficacy of Ciltacabtagene Autoleucel Versus Idecabtagene Vicleucel in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma Previously Treated with 2-4 Prior Lines of Therapy Using a Matching-Adjusted Indirect Comparison
Bar N, Diels J, van Sanden S, Mendes J, Hernando T, Cost P, Schecter J, Lendvai N, Patel N, Ishida T, Er J, Harrison S, Lopez-Muñoz N. Comparative Efficacy of Ciltacabtagene Autoleucel Versus Idecabtagene Vicleucel in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma Previously Treated with 2-4 Prior Lines of Therapy Using a Matching-Adjusted Indirect Comparison. Blood 2023, 142: 2141. DOI: 10.1182/blood-2023-182141.Peer-Reviewed Original ResearchIndividual patient-level dataMatching-adjusted indirect comparisonProgression-free survivalRefractory multiple myelomaCARTITUDE-1Overall response rateMultiple myelomaUnanchored matching-adjusted indirect comparisonIdecabtagene vicleucelHazard ratioCAR-TsKaplan-MeierComparative efficacyIndirect comparisonConfidence intervalsChimeric antigen receptor T-cell therapyB-cell maturation antigenCox proportional hazards modelGood partial responseTreatment of patientsT-cell therapyWeighted logistic regression analysisProportional hazards modelPatient-level dataLogistic regression analysis